About Repligen
Repligen is a company based in Waltham (United States) founded in 1981 by Paul Schimmel and Alexander Rich.. The company has 1,780 employees as of December 31, 2024. Repligen has completed 11 acquisitions, including ARTeSYN, ATOLL-bio and Avitide. Repligen offers products and services including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns. Repligen operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 1780 as on 31 Dec, 2024
- Founders Paul Schimmel, Alexander Rich
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Repligen Corporation
-
Annual Revenue
$634.44 M0.33as on Dec 31, 2024
-
Net Profit
$-25.51 M-171.68as on Dec 31, 2024
-
EBITDA
$109.21 M-19.37as on Dec 31, 2024
-
Latest Funding Round
$238.59 M (USD), Post-IPO
Aug 01, 2017
- Investors
-
Employee Count
1780
as on Dec 31, 2024
-
Investments & Acquisitions
ARTeSYN
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Repligen
Repligen is a publicly listed company on the NASDAQ with ticker symbol RGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Repligen
Repligen offers a comprehensive portfolio of products and services, including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for cell culture intensification in bioprocessing
Systems for tangential flow filtration in drug manufacturing
Columns for efficient protein purification processes
Unlock access to complete
Unlock access to complete
Software Development Team
61 people
Leadership Team
50 people
Product Management Team
28 people
Senior Team
27 people
Human Resources and Administration
21 people
Finance and Accounting
14 people
Sales and Marketing
9 people
Operations Team
8 people
Unlock access to complete
Funding Insights of Repligen
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $238.6M
-
First Round
First Round
(15 Dec 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2017 | Amount | Post-IPO - Repligen | Valuation |
investors |
|
| May, 2016 | Amount | Post-IPO - Repligen | Valuation |
investors |
|
| Jun, 2014 | Amount | Post-IPO - Repligen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Repligen
Repligen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Muscular Dystrophy Association. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A community foundation dedicated to advancing cures for neuromuscular diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Repligen
Repligen has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include ARTeSYN, ATOLL-bio and Avitide. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tools for self-assembly based ordered nanostructures are developed.
|
2014 | ||||
|
Disposable fluid management systems for bioprocessing are developed and manufactured.
|
2012 | ||||
|
Affinity purification solutions are developed for biopharmaceutical applications.
|
2012 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Repligen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Repligen Comparisons
Competitors of Repligen
Repligen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Repligen
Frequently Asked Questions about Repligen
When was Repligen founded?
Repligen was founded in 1981 and raised its 1st funding round 29 years after it was founded.
Where is Repligen located?
Repligen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of Repligen?
Olivier Loeillot is the current CEO of Repligen.
How many employees does Repligen have?
As of Dec 31, 2024, the latest employee count at Repligen is 1,780.
What is the annual revenue of Repligen?
Annual revenue of Repligen is $634.44M as on Dec 31, 2024.
What does Repligen do?
Repligen was founded in 1981 and is headquartered in Waltham, United States. Bioprocessing technologies and reagents for the production of biologic drugs, including monoclonal antibodies, are developed and manufactured by the company. Key offerings include Protein A for antibody purification, growth factor products, and OPUS single-use chromatography columns. Operations focus on supporting purification processes in the biopharmaceutical sector.
Who are the top competitors of Repligen?
Repligen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Repligen offer?
Repligen offers XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns.
Is Repligen publicly traded?
Yes, Repligen is publicly traded on NASDAQ under the ticker symbol RGEN.
How many acquisitions has Repligen made?
Who are Repligen's investors?
Repligen has 1 investor. Key investors include Muscular Dystrophy Association.
What is Repligen's ticker symbol?
The ticker symbol of Repligen is RGEN on NASDAQ.